Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO...
You are being redirected to the original discussion. Please continue if you want to read the full post.
Continue to original articleYou will be redirected in 3 seconds.